Experimental antibody targets deadly staph infections

NCT ID NCT02357966

Completed Disease control Sponsor: XBiotech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a lab-made antibody called 514G3 in 52 hospitalized adults with Staphylococcus aureus bloodstream infections. Participants received either a single dose of the antibody plus standard antibiotics or a placebo plus antibiotics. The main goals were to check safety and find the best dose. Results are not yet available, but the trial aims to see if adding this antibody can help clear the infection more effectively.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 514G3 (a human monoclonal antibody) given as a single intravenous dose alongside standard antibiotics
What this could lead to: If successful, this antibody could become an add-on treatment to help clear Staph bloodstream infections faster and more safely.
What could go wrong: This is an early-phase trial with only 52 participants, so results may not apply broadly. The antibody is experimental and may not improve outcomes over antibiotics alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAPHYLOCOCCUS AUREUS BACTEREMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bacterial infectious disease with sepsis staphylococcal infection staphylococcus aureus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STAPHYLOCOCCUS AUREUS BACTEREMIA

Contacts and locations

Locations

XBiotech Investigative Site

Columbus, Georgia, 31904, United States
XBiotech Investigative Site

Charlotte, North Carolina, 28203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.